GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $14.20 Average PT from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has earned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $14.20.

GOVX has been the topic of a number of recent research reports. Alliance Global Partners initiated coverage on shares of GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price on the stock. Noble Financial raised their price target on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research note on Monday, August 19th. D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th.

GeoVax Labs Price Performance

Shares of NASDAQ GOVX opened at $2.45 on Friday. The firm’s 50-day moving average price is $2.31 and its two-hundred day moving average price is $2.73. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same period in the prior year, the business earned ($4.80) EPS. On average, analysts predict that GeoVax Labs will post -4.49 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs at the end of the most recent reporting period. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.